Arkolith/Insider Trading/TNGX/Form 4

Crystal Adam

President, R&DTango Therapeutics, Inc. (TNGX) · full profile →Form 4 · filed Mar 27, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$241K
Net Open-Market Flow
-$241K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 25, 2026Option exercise(M)12K$5.20$62K125K
Mar 25, 2026Sell(S)12K$20.11$241K113K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 25, 2026Option exercise(M)12K—$0461K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-129990) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML